Psilocybin in Bipolar II Study Provides Preliminary Data on Safety

JAMA Psychiatry. 2024 Jun 1;81(6):541-542. doi: 10.1001/jamapsychiatry.2023.4680.

Authors

David B Yaden¹, Natalie Gukasyan², Sandeep M Nayak¹

Affiliations

¹ Center for Psychedelic and Consciousness Research, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland.
² Columbia University Medical Center, New York State Psychiatric Institute, New York.

PMID: 38055240
DOI: 10.1001/jamapsychiatry.2023.4680

No abstract available

Publication types

Randomized Controlled Trial

MeSH terms

Bipolar Disorder* / drug therapy
Hallucinogens* / adverse effects
Humans
Psilocybin* / adverse effects
Psilocybin* / pharmacology

Substances

Psilocybin
Hallucinogens